Search Results - "Novak, U"

Emotion recognition in Huntington's disease: A systematic review by HENLEY, Susie M. D, NOVAK, Marianne J. U, FROST, Chris, KING, John, TABRIZI, Sarah J, WARREN, Jason D

“…There is increasing interest in the nature of the emotion recognition deficit in Huntington's disease (HD). There are conflicting reports of disproportionate…”
Get full text

Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease by NOVAK, Marianne J. U, WARREN, Jason D, HENLEY, Susie M. D, DRAGANSKI, Bogdan, FRACKOWIAK, Richard S, TABRIZI, Sarah J

“…Huntington's disease is an inherited neurodegenerative disease that causes motor, cognitive and psychiatric impairment, including an early decline in ability…”
Get full text

Efficacy and toxicity of CAR T‐cell therapy in patients with primary and secondary central nervous system lymphoma—an analysis of the EBMT Lymphoma WP and the GoCART coalition by Laube, A., Fuhrmann, S., Peczynski, C., Boumendil, A., Michel, E., Finel, H., Galimard, J., Beauvais, D., Daskalakis, M., Novak, U., Kröger, N., Stelljes, M., Tresckow, B., Wulf, G. G., Dreger, P., Sureda, A., Schmitz, N., Glaß, B.

Get full text

17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023 by Laube, A, Fuhrmann, S, Peczynski, C, Boumendil, A, Michel, E, Finel, H, Galimard, J, Beauvais, D, Daskalakis, M, Novak, U, Kröger, N, Stelljes, M, von Tresckow, B, Wulf, G G, Dreger, P, Sureda, A, Schmitz, N, Glaß, B

“…Introduction: The prognosis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and involvement of the central nervous system (CNS) remains dismal…”
Get full text

SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY by Østenstad, B., Pirosa, M. C., Schär, S., Brodtkorb, M., Wahlin, B. E., Hernberg, M., Pedersen, M., Stathis, A., Zander, T., Novak, U., Zenz, T., Fischer, N., Krasniqi, F., Hitz, F., Jjohansson, A., Lofgren, D., Meyer, P., Bjørnevik, A. T., Hayoz, S., Scheibe, B., Steiner, L., Dirnhofer, S., Ceriani, L., Zucca, E.

Get full text

LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE by Nastoupil, L. J., Kamdar, M., Chavez, J. C., Ghesquieres, H., Ghosh, M., Holmes, H., López‐Guillermo, A., Martínez‐López, J., Novak, U., Ribrag, V., Roddie, C., Waller, E. K., Feldman, T., Rosenthal, A. C., Sauter, C., Bonin, M., Karmali, R., Montheard, S., Previtali, A., Abramson, J.

Get full text

SAKK 38/19: ASSESSING A CTDNA AND PET‐ORIENTED THERAPY IN PATIENTS WITH DLBCL. A MULTICENTER, OPEN‐LABEL, PHASE II TRIAL by Stathis, A., Hitz, F., Schär, S., Novak, U., Fischer, N., Mey, U., Gritti, G., Zander, T., Lang, N., Cairoli, A., Zenz, T., Rhyner, G., Mingrone, W., Schmidt, A., Gaidano, G., Hohaus, S., Stern, A. O., Mamot, C., Bruscagin, A., Musilova, J., Hayoz, S., Bertoni, F., Zucca, E., Dirnhofer, S., Ceriani, L., Rossi, D.

Get full text

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10) by Hitz, F., Kraus, M., Pabst, T., Hess, D., Besse, L., Silzle, T., Novak, U., Seipel, K., Rondeau, S., Stüdeli, S., Vilei, S. Berardi, Samaras, P., Mey, U., Driessen, C.

“…The antiretroviral agent nelfinavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II trial investigated whether adding…”
Get full text

NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma by Jeker, B, Novak, U, Mansouri Taleghani, B, Baerlocher, G M, Seipel, K, Mueller, B U, Bigler, M, Betticher, D, Luethi, J-M, Farese, S, Ruefer, A, Pabst, T

“…Chemotherapy with G–CSF is used to mobilize peripheral stem cells in multiple myeloma (MM) patients, with plerixafor as a rescue strategy for poorly mobilizing…”
Get full text

Evaluation of Diffusion Coefficient Determination using a Microfluidic Device by Miložič, N., Lubej, M., Novak, U., Žnidaršič-Plazl, P., Plazl, I.

“…A theoretical description of the convection-diffusion process in a homogeneous system enabling estimation of diffusion coefficients employing commercially…”
Get full text

R‐CODOX‐M/R‐IVAC VERSUS DA‐EPOCH‐R IN PATIENTS WITH NEWLY DIAGNOSED HIGH‐RISK BURKITT LYMPHOMA: FINAL RESULTS OF A MULTI‐CENTER RANDOMIZED HOVON/SAKK TRIAL by Chamuleau, M., Stenner, F., Chitu, D., Novak, U., Minnema, M., Visser, O., Stevens, W., Zenz, T., Imhoff, G., Wu, K., Demandt, A., Kersten, M. J., Terpstra, W., Tick, L., Deeren, D., Neste, E., Gregor, M., Veelken, H., Bohmer, L., Casper, C., Dirnhofer, S., Brand, M., Jong, D., Nijland, M., Lugtenburg, P.

Get full text

Toxicities at one year follow‐up in patients with advanced stage classical Hodgkin Lymphoma: results from the randomized phase III HD21 trial by the German Hodgkin Study Group by Ferdinandus, J., Moccia, A. A., Greil, R., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., Giri, P., Kamper, P., Molin, D., Kreissl, S., Fuchs, M., Behringer, K., Schneider, G., Rosenwald, A., Klapper, W., Eich, H. T., Baues, C., Hallek, M., Dietlein, M., Kobe, C., Diehl, V., Engert, A., Borchmann, P.

Get full text

BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: EFFICACY RESULTS OF THE GHSG PHASE III HD21 TRIAL by Borchmann, P., Moccia, A. A., Greil, R., Schneider, G., Hertzberg, M., Schaub, V., Hüttmann, A., Keil, F., Dierlamm, J., Hänel, M., Novak, U., Meissner, J., Zimmermann, A., Mathas, S., Zijlstra, J. M., Fosså, A., Viardot, A., Hertenstein, B., Martin, S., Giri, P., Kamper, P., Molin, D., Kreissl, S., Ferdinandus, J., Fuchs, M., Rosenwald, A., Klapper, W., Eich, H., Baues, C., Hallek, M., Dietlein, M., Kobe, C., Diehl, V., Engert, A.

Get full text

Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland by Moccia, A. A., Aeppli, S., Güsewell, S., Bargetzi, M., Caspar, C., Brülisauer, D., Ebnöther, M., Fehr, M., Fischer, N., Ghilardi, G., Krasniqi, F., Lang, N., Mey, U., Mingrone, W., Novak, U., Pfleger, C., Richter, P., Rütti, M., Schmidt, A., Stenner, F., Voegeli, M., Zander, T., Zucca, E., Hitz, F.

“…Hodgkin lymphoma (HL) in older patients appears to be a different disease compared with younger patients with historically lower survival rates. This is…”
Get full text

Hematopoietic stem cell remobilization with vinorelbine and filgrastim in AML by Blum, V, Heini, A D, Novak, U, Taleghani, B M, Baerlocher, G M, Leibundgut, K, Seipel, K, Banz, Y, Bargetzi, M, Pabst, T

Get full text

White matter integrity in premanifest and early Huntington's disease is related to caudate loss and disease progression by Novak, Marianne J.U., Seunarine, Kiran K., Gibbard, Clare R., Hobbs, Nicola Z., Scahill, Rachael I., Clark, Chris A., Tabrizi, Sarah J.

“…Huntington's disease (HD) is associated with progressive loss of caudate and white matter volume and integrity. Our aim was to systematically assess…”
Get full text

PREDICTIVE VALUE OF POD24 VALIDATION IN FOLLICULAR LYMPHOMA PATIENTS INITIALLY TREATED WITH CHEMOTHERAPY‐FREE REGIMENS IN A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS OF THE SWISS GROUP FOR CLINICAL CANCER RESEARCH (SAKK) by Moccia, A., Schär, S., Hayoz, S., Pirosa, M., Taverna, C., Novak, U., Kimby, E., Ghielmini, M., Zucca, E.

Get full text

SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK by Novak, U., Fehr, M., Schär, S., Dreyling, M., Scheubeck, G., Ramadan, S., Zucca, E., Zander, T., Hess, G., Mey, U., Ferrero, S., Mach, N., Boccomini, C., Böttcher, S., Voegeli, M., Cairoli, A., Menter, T., Dirnhofer, S., Gadient, S., Eckhardt, K., Driessen, C., Renner, C.

Get full text

Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53 by Grob, T J, Novak, U, Maisse, C, Barcaroli, D, Lüthi, A U, Pirnia, F, Hügli, B, Graber, H U, De Laurenzi, V, Fey, M F, Melino, G, Tobler, A

“…Inactivation of the tumour suppressor p53 is the most common defect in cancer cells. p53 is a sequence specific transcription factor that is activated in…”
Get full text

GENETIC AND PHENOTYPIC ATTRIBUTES OF SPLENIC MARGINAL ZONE LYMPHOMA by Bonfiglio, F., Bruscaggin, A., Guidetti, F., Terzi di Bergamo, L., Faderl, M., Spina, V., Condoluci, A., Bonomini, L., Forestieri, G., Koch, R., Piffaretti, D., Pini, K., Pirosa, M. C., Cittone, M. G., Arribas, A., Lucioni, M., Ghilardi, G., Wu, W., Arcaini, L., Baptista, M. J., Bastidas, G., Bea, S., Boldorini, R., Broccoli, A., Canzonieri, V., Cascione, L., Ceriani, L., Cogliatti, S., Derenzini, E., Devizzi, L., Dietrich, S., Elia, A. R., Facchetti, F., Gaidano, G., Garcia, J. F., Gerber, B., Ghia, P., Da Silva, M. G., Gritti, G., Guidetti, A., Hitz, F., Inghirami, G., Ladetto, M., Lopez‐Guillermo, A., Lucchini, E., Maiorana, A., Marasca, R., Matutes, E., Meignin, V., Merli, M., Moccia, A., Mollejo, M., Montalban, C., Novak, U., Oscier, D. G., Passamonti, F., Piazza, F., Pizzolitto, S., Sabattini, E., Salles, G., Santambrogio, E., Scarfó, L., Stathis, A., Stüssi, G., Geyer, J. T., Tapia, G., Thieblemont, C., Tousseyn, T., Tucci, A., Visco, C., Vitolo, U., Zenz, T., Zinzani, P. L., Khiabanian, H., Calcinotto, A., Bertoni, F., Bhagat, G., Campo, E., De Leval, L., Dirnhofer, S., Pileri, S. A., Piris, M. Án., Traverse‐Glehen, A., Tzankov, A., Paulli, M., Ponzoni, M., Mazzucchelli, L., Cavalli, F., Zucca, E., Rossi, D.

Get full text